204 related articles for article (PubMed ID: 35793874)
1. Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study.
Shui IM; Liu XQ; Zhao Q; Kim ST; Sun Y; Yearley JH; Choudhury T; Webber AL; Krepler C; Cristescu R; Lee J
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793874
[TBL] [Abstract][Full Text] [Related]
2. Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis.
Loi S; Salgado R; Schmid P; Cortes J; Cescon DW; Winer EP; Toppmeyer DL; Rugo HS; De Laurentiis M; Nanda R; Iwata H; Awada A; Tan AR; Sun Y; Karantza V; Wang A; Huang L; Saadatpour A; Cristescu R; Yearley J; Lunceford J; Jelinic P; Adams S
JCO Precis Oncol; 2023 Apr; 7():e2200317. PubMed ID: 37099733
[TBL] [Abstract][Full Text] [Related]
3. Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy.
Iga N; Otsuka A; Hirata M; Kataoka TR; Irie H; Nakashima C; Matsushita S; Uchi H; Yamamoto Y; Funakoshi T; Fujisawa Y; Yoshino K; Fujimura T; Hata H; Ishida Y; Kabashima K
Cancer Sci; 2019 Nov; 110(11):3434-3441. PubMed ID: 31509303
[TBL] [Abstract][Full Text] [Related]
4. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
5. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
[TBL] [Abstract][Full Text] [Related]
6. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK
J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521
[TBL] [Abstract][Full Text] [Related]
7. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.
Tang B; Yan X; Sheng X; Si L; Cui C; Kong Y; Mao L; Lian B; Bai X; Wang X; Li S; Zhou L; Yu J; Dai J; Wang K; Hu J; Dong L; Song H; Wu H; Feng H; Yao S; Chi Z; Guo J
J Hematol Oncol; 2019 Jan; 12(1):7. PubMed ID: 30642373
[TBL] [Abstract][Full Text] [Related]
8. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma.
Haddad RI; Seiwert TY; Chow LQM; Gupta S; Weiss J; Gluck I; Eder JP; Burtness B; Tahara M; Keam B; Kang H; Muro K; Albright A; Mogg R; Ayers M; Huang L; Lunceford J; Cristescu R; Cheng J; Mehra R
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217573
[TBL] [Abstract][Full Text] [Related]
9. [Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma].
Adam J; Tomasic G; Robert C
Ann Pathol; 2017 Feb; 37(1):55-60. PubMed ID: 28111041
[TBL] [Abstract][Full Text] [Related]
10. Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort.
Bai X; Kim M; Kasumova G; Si L; Tang B; Cui C; Yang X; Wei X; Cohen J; Lawrence D; Freedman C; Fadden R; Rubin K; Sharova T; Frederick D; Flaherty K; Sullivan R; Guo J; Boland G
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33632901
[TBL] [Abstract][Full Text] [Related]
11. Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer.
Fenor de la Maza MD; Chandran K; Rekowski J; Shui IM; Gurel B; Cross E; Carreira S; Yuan W; Westaby D; Miranda S; Ferreira A; Seed G; Crespo M; Figueiredo I; Bertan C; Gil V; Riisnaes R; Sharp A; Rodrigues DN; Rescigno P; Tunariu N; Liu XQ; Cristescu R; Schloss C; Yap C; de Bono JS
Eur Urol Oncol; 2022 Dec; 5(6):659-667. PubMed ID: 35491356
[TBL] [Abstract][Full Text] [Related]
12. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Goodman AM; Kato S; Bazhenova L; Patel SP; Frampton GM; Miller V; Stephens PJ; Daniels GA; Kurzrock R
Mol Cancer Ther; 2017 Nov; 16(11):2598-2608. PubMed ID: 28835386
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of combined radiotherapy and anti-programmed death 1 therapy in acral and mucosal melanoma.
Kato J; Hida T; Someya M; Sato S; Sawada M; Horimoto K; Fujioka M; Minowa T; Matsui Y; Tsuchiya T; Kitagawa M; Nakata K; Sakata KI; Torigoe T; Uhara H
J Dermatol; 2019 Apr; 46(4):328-333. PubMed ID: 30758859
[TBL] [Abstract][Full Text] [Related]
14. High response rate to PD-1 blockade in desmoplastic melanomas.
Eroglu Z; Zaretsky JM; Hu-Lieskovan S; Kim DW; Algazi A; Johnson DB; Liniker E; Ben Kong ; Munhoz R; Rapisuwon S; Gherardini PF; Chmielowski B; Wang X; Shintaku IP; Wei C; Sosman JA; Joseph RW; Postow MA; Carlino MS; Hwu WJ; Scolyer RA; Messina J; Cochran AJ; Long GV; Ribas A
Nature; 2018 Jan; 553(7688):347-350. PubMed ID: 29320474
[TBL] [Abstract][Full Text] [Related]
15. Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration.
Hu-Lieskovan S; Braiteh F; Grilley-Olson JE; Wang X; Forgie A; Bonato V; Jacobs IA; Chou J; Johnson ML
Target Oncol; 2021 Nov; 16(6):773-787. PubMed ID: 34694529
[TBL] [Abstract][Full Text] [Related]
16. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
17. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
18. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Daud AI; Wolchok JD; Robert C; Hwu WJ; Weber JS; Ribas A; Hodi FS; Joshua AM; Kefford R; Hersey P; Joseph R; Gangadhar TC; Dronca R; Patnaik A; Zarour H; Roach C; Toland G; Lunceford JK; Li XN; Emancipator K; Dolled-Filhart M; Kang SP; Ebbinghaus S; Hamid O
J Clin Oncol; 2016 Dec; 34(34):4102-4109. PubMed ID: 27863197
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma.
Ogata D; Haydu LE; Glitza IC; Patel SP; Tawbi HA; McQuade JL; Diab A; Ekmekcioglu S; Wong MK; Davies MA; Amaria RN
Cancer Med; 2021 Apr; 10(7):2293-2299. PubMed ID: 33686688
[TBL] [Abstract][Full Text] [Related]
20. Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1/PD-L1 axis.
Wrede N; Hoffmann I; Vollbrecht C; Koch I; Wolkenstein P; Klauschen F; Capper D; von Laffert M; Jurmeister P
Pathol Res Pract; 2022 Jan; 229():153689. PubMed ID: 34844086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]